Fresenius SE Income from Continuous Operations 2016-2024 | FSNUY
Fresenius SE annual/quarterly income from continuous operations history and growth rate from 2016 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Fresenius SE income from continuous operations for the quarter ending June 30, 2024 was $-0.013B, a 107.14% decline year-over-year.
- Fresenius SE income from continuous operations for the twelve months ending June 30, 2024 was $-0.120B, a 107.31% decline year-over-year.
- Fresenius SE annual income from continuous operations for 2023 was $0.258B, a 88.45% decline from 2022.
- Fresenius SE annual income from continuous operations for 2022 was $2.23B, a 33.12% decline from 2021.
- Fresenius SE annual income from continuous operations for 2021 was $3.335B, a 3.42% increase from 2020.
Fresenius SE Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$258 |
| 2022 |
$2,230 |
| 2021 |
$3,335 |
| 2020 |
$3,225 |
| 2019 |
$3,392 |
| 2018 |
$4,386 |
| 2017 |
$3,428 |
| 2016 |
$2,981 |
| 2015 |
$2,551 |
Fresenius SE Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$-13 |
| 2024-03-31 |
$314 |
| 2023-12-31 |
$-589 |
| 2023-09-30 |
$169 |
| 2023-06-30 |
$181 |
| 2023-03-31 |
$497 |
| 2022-12-31 |
$403 |
| 2022-09-30 |
$555 |
| 2022-06-30 |
$600 |
| 2022-03-31 |
$672 |
| 2021-12-31 |
$870 |
| 2021-09-30 |
$803 |
| 2021-06-30 |
$853 |
| 2021-03-31 |
$809 |
| 2020-12-31 |
$739 |
| 2020-09-30 |
$874 |
| 2020-06-30 |
$806 |
| 2020-03-31 |
$805 |
| 2019-12-31 |
$926 |
| 2019-09-30 |
$840 |
| 2019-06-30 |
$816 |
| 2019-03-31 |
$811 |
| 2018-12-31 |
$1,027 |
| 2018-09-30 |
$813 |
| 2018-06-30 |
$1,689 |
| 2018-03-31 |
$858 |
| 2017-12-31 |
$1,030 |
| 2017-09-30 |
$809 |
| 2017-06-30 |
$790 |
| 2017-03-31 |
$800 |
| 2016-12-31 |
$851 |
| 2016-09-30 |
$758 |
| 2016-06-30 |
$734 |
| 2016-03-31 |
$638 |
| 2015-12-31 |
$393 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.458B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
